NordiQC EQA Data and Observations for PD-L1 Biomarker Testing By Søren Nielsen, Director, NordiQC Immune-checkpoint inhibitors targeting PD-1 or PD-L1 as pembrolizumab, nivolumab, durvalumab and atezolizumab have since 2016 been approved for multiple cancers as lung carcinoma, urothelial carcinoma, melanoma, breast carcinoma and many other solid cancers. At present Immunohistochemistry (IHC) for PD-L1 expression is read more…
Category Archives: PD-L1
Welcome back to NordiQC. Now offers PD-L1 IHC Fit-For-Purpose Proficiency Testing
PD-L1 IHC testing has a significant impact on patient eligibility for tailored specific immune oncology and require high diagnostic accuracy. This also underlines the need of appropriate EQA methods to evaluate the performance of PD-L1 IHC testing among the participating laboratories. At present, PD-L1 IHC testing is based on the “3D-approach” aligning Drug, Disease and read more…
IQN Path PD-L1 digital educational resource for EQA
IQN Path is working on setting up a new project to support quality of PDL1 testing. The goal of the project, is to establish a high quality education resource for self-assessment of pathologists on PD-L1 scoring. Digital slides stained with the four different FDA approved tests (from both Agilent and Roche) will be available to view. The digital platform read more…
The third IQN Path In-situ Methods working group meeting
On Friday 1st September, prior to the European Congress of Pathology meeting, IQN Path held its 3rd In-situ Methods working group face to face meeting. Prof Mogens Vyberg (NordiQC) and John Garratt (CIQC) chaired the session. The agenda opened with a short summary on the progress of IQN Path’s activities and discussions of the Working Group read more…